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https://doi.org/10.1016/j.patter.2021.100264THE BIGGER PICTURE Non-pharmaceutical interventions (NPI) are, and will remain, decisive tools to
contain the spread of SARS-CoV-2. Besides quarantine and isolation, diagnostic testing can be used to
inform decisions on the release from, or continuation of, an isolation period. We developed a flexible soft-
ware tool, the COVIDStrategyCalculator, which allows one to compute the efficacy of user-defined NPI stra-
tegies with regard to preventing SARS-CoV-2 onward transmission in different settings. By synthesizing the
available knowledge onwithin-host viral dynamics, the software is intended to help decisionmakers in iden-
tifying suitable NPI strategies for SARS-CoV-2 containment, containment of novel variants or the utilization
of novel diagnostics as part of national or supra-national NPI guidelines.
Development/Pre-production: Data science output has been
rolled out/validated across multiple domains/problemsSUMMARYWhile large-scale vaccination campaigns against SARS-CoV-2 are rolled out at the time of writing, non-phar-
maceutical interventions (NPIs), including the isolation of infected individuals and quarantine of exposed
individuals, remain central measures to contain the spread of SARS-CoV-2. Strategies that combine NPIs
with innovative SARS-CoV-2 testing strategiesmay increase containment efficacy and help to shorten quaran-
tine durations. We developed a user-friendly software tool that implements a recently published stochastic
within-host viral dynamicsmodel that captures temporal attributesof the viral infection, suchas test sensitivity,
infectiousness, and the occurrence of symptoms. Based on this model, the software allows to evaluate the ef-
ficacy of user-defined, arbitrary NPI and testing strategies in reducing the transmission potential in different
contexts. The software thusenablesdecisionmakers to exploreNPI strategies andperformhypothesis testing,
e.g., with regard to the utilization of novel diagnostics or with regard to containing novel virus variants.INTRODUCTION
Non-pharmaceutical interventions (NPIs) are important tools to
prevent SARS-CoV-2 transmission and contain the spread of
novel variants. NPIs consist of quarantine, isolation, and diag-
nostic testing of (potentially) infected individuals. The term
‘‘quarantine’’ refers to the separation of people who are at risk
of being infected with SARS-CoV-2 due to potential exposure,
but whose infection status is unknown. Examples include the
management of incoming travelers from high-risk areas, or theThis is an open access article under the CC BY-Nmanagement of individuals who have been in contact with
confirmed cases. The term ‘‘isolation,’’ refers to the separation
of individuals with a confirmed infection. NPI strategies may
also combine quarantine, isolation, and SARS-CoV-2 testing to
improve efficacy, or shorten quarantine durations.
For quarantine, WHO recommends a length of 14 days1 and
for isolation, a length of at least 13 days.2 However, at the na-
tional, sub-national, or institutional level different strategies are
often implemented. This may be due to perceived socioeco-




Figure 1. Intra-host viral dynamics
(A) Stochastic transit compartment model of intra-
host viral dynamics. Model details are provided in
an associated article.6
(B–D) Model simulation with regard to time-depen-
dent (B) virus detectability by PCR, (C) infectious-
ness, and (D) the probability of experiencing
symptoms.
ll
OPEN ACCESS DescriptorIn these settings, testing is frequently used to shorten the dura-
tion of quarantine and/or isolation. Given that antigen-based
rapid diagnostic tests (RDT) are being used increasingly,5 strate-
gies that are based on combined testing and quarantine/isola-
tion criteria may gain even more momentum in the near future.
To enable the design and evaluate the efficacy of NPI strate-
gies in preventing the risk of onward transmission, we present
the COVIDStrategyCalculator software. The software imple-
ments a stochastic intra-host SARS-CoV-2 dynamics model,
presented in an associated article6, to assess arbitrary, user-
defined, NPI strategies ‘‘on the fly.’’ The software focuses on
three common scenarios in policy making: (i) contact person
management, (ii) quarantine of incoming travelers, and (iii) isola-
tion strategies.
The COVIDStrategyCalculator software can be run in the
browser (https://COVIDStrategyCalculator.github.io), or be
downloaded as an offline version for Mac, Linux, and Windows
(https://github.com/COVIDStrategyCalculator/COVIDStrategyC
alculator). The software allows full flexibility with regard to param-
eter choices of the underlying model, which, for example, deter-
mine the time course of infection (e.g., the average ‘‘incubation
time’’ or the ‘‘time of infectiousness’’), the proportion of asymp-
tomatic cases, the test sensitivity, and much more. However, a
set of default parameters has been derived in an associated
article6 that synthesizes the current knowledge on within-host
infection dynamics of SARS-CoV-2 and temporal test sensitivity.
NPI modeling studies7–12 often present particular pre-
computed NPI scenarios. This leaves policy makers the choice
to either accept all assumptions of a pre-computed scenario, im-
plementing it into a national guideline, or to try to interpolate be-
tween the pre-computation assumptions and the actual situation
faced.Bothapproaches leaveaknowledgegap thatprecludes the
analysis of the exact NPI strategy in question. The COVIDStrate-
gyCalculator fills this void by allowing the user to define an arbi-
traryNPI strategy and toevaluate its efficacy inpreventing onward
transmission. The COVIDStrategyCalculator therefore facilitates
the rational, evidence-based design of non-pharmaceutical con-
trol strategies.2 Patterns 2, 100264, June 11, 2021RESULTS
Intra-host viral dynamics
The COVIDStrategyCalculator analytically
solves a stochastic transit compartment
model (Figure 1A) of theSARS-CoV-2 infec-
tion time course. The underlying transit
compartment model consists of different
phases that resemble relevant attributes of
the infection: i.e., whether the virus is (i)
detectable, the individual (ii) has symptoms,and (iii) may be infectious. In an associated article6, we describe
the mathematical details of the model, and exemplify the estima-
tion of default parameters that capture clinically observed tempo-
ral changes and variability in test sensitivities, incubation and
infectious periods, as well as times to symptom onset.
In essence, for user-defined parameters, non-pharmaceutical
interventions (‘‘symptom screening’’ and testing) and initial states
(exemplified below in configuring and simulating an NPI strategy)
COVIDStrategyCalculator internally computes the probability
over time of the aforementioned attributes (i–iii) based on the sto-
chastic intra-hostmodel (Figure1A). An example is given inFigures
1B–1D: in this simulation, infection occurred at time t0 = 0. Fig-
ure 1B shows the probability that the virus is detectable by PCR
(= temporal test sensitivity); Figure 1C depicts the probability that
the individual is infectious (= able to disseminate infectious parti-
cles); and Figure 1D depicts the probability that the individual is
symptomatic. Forany timepoint, e.g., 14dayspost-infection (black
dashed line in Figures 1B–1D), it is possible to compute the virus
detection probability, the probability that an individual is infectious
and has symptoms. The detection probability (Figure 1B) and the
probability to have symptoms (Figure 1C) are relevant for different
NPIs, e.g., diagnostic testing and ‘‘symptom screening,’’ whereas
the probability to be infectious (Figure 1C) determines whether in-
dividuals may transmit the virus, and is thus used to compute the
efficacy of NPIs in reducing the transmission potential.
Software outputs
The COVIDStrategyCalculator allows to compute the efficacy of
user-defined NPI strategies. Efficacy refers to reducing the
transmission potential emanating from an individual (= ‘‘risk
reduction’’):
efficacy = risk reduction= 1 relative risk: (Equation 1)
Mathematically, the ‘‘relative risk’’ is computed as the residualtransmission risk that remains after a user-defined NPI strategy,
relative to the transmission risk in a baseline scenario, where no
NPIs are imposed (an example is given in the associated article6,
Figure 2 therein):
Figure 2. Screenshot of the COVIDStrategyCalculator
Themain window consists of four components: time course trajectories (1), test efficacy reports (2), a result log (3), and user input (4). Reported results include the











where the nominator integrates over the conditional probability
of being infectious after release from an NPI (e.g., quarantine)
at time tend, whereas the nominator integrates over the probabil-
ity of being infectious in the case where individuals had not been
isolated, or put into quarantine (baseline risk). Notably, the rela-
tive riskmetric above is independent of the initial prevalence (see
also the associated paper6 for details). Importantly, in the equa-
tion abovewe assume no additional (e.g., behavioral) differences
between the two settings.
When simulating a user-defined NPI strategy, the profile of the
percent relative riskwill be depicted togetherwith the time-depen-
dent diagnostic assay sensitivity Pðpositive test j infectedÞ as
shown in Figure 2, field 1). The latter is intended to visually ease
the selection of times to perform diagnostic tests together with
the table below the graphic Figure 2, field 2), which assesses
the assays’ ability to filter out infectious individuals
Pðinfectious j positive test Þ. We differentiate between the two
quantities because PCR assays may allow virus detection for a
prolonged timeafter symptomonset, duringwhich the secretedvi-
rus often is no longer infectious. The table in Figure 2, field 3) logs
the summary of the conducted simulations and outputs the
following numeric values (i) the probability to be infectious at the
time point where the quarantine or isolation ends Ptend ðInfÞ, (ii) the
‘‘% relative transmission risk’’ as defined above, and (iii) the ‘‘%
risk reduction’’ (= efficacy of the NPI). For each metric (Figure 2,fields 2 and 3), three values are reported that indicate the result
in the case of a ‘‘typical’’ infection (typical parameters as outlined
below), as well as an uncertainty range based on the provided
lower and upper extreme parameter values. For the graphics (Fig-
ure 2, field 1), the uncertainty range (lower and upper extreme dy-
namics) is visualized by the shaded area. We further discuss the
parameters of the software and the underlyingmodeling assump-
tions by describing how to use the COVIDStrategyCalculator.
In Figure 2, field 4, the user can configure an arbitrary NPI
strategy as outlined below.
Software utilization
Figure 3A shows a zoom of the opening window: the different
tabs allow to evaluate a strategy (1), set parameters (2), or
perform a prevalence estimation (3). In field (4), the user can
select between the different modes of the software.
Configuring and simulating an NPI strategy
The COVIDStrategyCalculator has three modes of operation,
corresponding to the three common scenarios in policy making:
(1) quarantine for contact management, (2) isolation of infected
individuals, and (3) quarantine for incoming travelers. Themodes
differ in the initial states used for simulation. In the ‘‘contact man-
agement’’ and the ‘‘isolation’’ mode, the simulation starts from a
point distribution, whereas in the ‘‘incoming travelers’’ mode as-
sumes a mix of ‘‘infection ages.’’
(1) In the contactmanagementmode, strategies aim to reduce
the risk emanating from individualswhohavebeen in recentPatterns 2, 100264, June 11, 2021 3
Figure 3. User input panels of the COVIDStrategyCalculator
(A) Zoom-in on the NPI configuration window.
(B) Model parameter input tab.
(C) Prevalence estimator input tab. Details of the usage and meaning of the different input fields are provided in the text.
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OPEN ACCESS Descriptorcontact with a confirmed case. In this scenario, the time of
the putative infection is known and can be entered by the
user (Figure 3A, field 6). In the underlyingmodel (Figure 1A),
all states are set to zero, except the very first compartment
of themodel,which is set to the initial probability of infection
provided in (Figure 3A, field 5). It is important to note here
that the NPI efficacy estimates (‘‘relative risk,’’ ‘‘risk reduc-
tion’’) are independent of the initial probability of infection,
as they cancel out when computing these relative quanti-
ties. The user selects a duration of quarantine (7) and
whether ‘‘symptom screening’’ is performed (checkbox
in 8). ‘‘Symptom screening’’ would imply that individuals
who develop symptoms go into isolation (in line with WHO
guidelines1,2,5) and no longer pose a risk, whereas individ-
uals who do not develop symptoms are released into soci-
ety at the end of the quarantine andmay continue to pose a
risk. The percentage of asymptomatic infections, which
would bemissed in ‘‘symptomscreening,’’ canbeprovided
by the user (outlined below). The expected level of adher-
ence (= which percentage of individuals follows the pro-
posed NPI) can be set in field (9). The level of adherence














(Equation 3)4 Patterns 2, 100264, June 11, 2021The user can also decide on whether diagnostic tests
should be conducted during the quarantine (check boxes
in field 10) and select whether PCR tests (default) or anti-
gen-based RDT should be performed (field 11). In the
case of a positive test, it is assumed that the individuals
go into isolation and no longer pose a risk. Individuals
who are tested false negative are assumed to stay quaran-
tined until the end of the user-defined quarantine duration
and are subsequently released into society. Therefore, the
time-dependent false omission rate (= 1-sensitivity) of the
test(s) is critical to determining the efficacy of testing during
NPIs. Parameters related to the diagnostic test can be
modified by the user as outlined below. The output of the
configuredNPI is shown immediately uponpressing ‘‘Run.’’
(2) In the isolationmode, the user can assess strategies for the
duration of isolation after symptom onset. In this scenario,
the time of symptom onset is known and can be entered by
the user (Figure 3A, field 7). In the underlying model (Fig-
ure 1A), all states are set to zero, except the very first
‘‘symptom compartment,’’ which is set to probability of
infection provided in Figure 3A, field 5. The user’s options
are similar to the mode described above, with the excep-
tion that a ‘‘symptomatic’’ screening is not possible.
(3) When choosing the incoming travelers mode (field 4 in
Figure 3A), the user is taken to the prevalence estimation
subroutine of the software (Figure 3C). The prevalence
estimation subroutine can be used on its own, or to
generate a population with mixed ‘‘infection age’’ for the
ll
OPEN ACCESSDescriptoranalysis of NPI strategies. The details are outlined below.
To use the mixed population, the user presses ‘‘estimate
prevalence’’ (Figure 3C, field 24) to generate an initial
probability distribution (depicted in Figure 3C, field 25),
which can be used (Figure 3C, field 26) for simulation Fig-
ure 3A. After setting the initial probability distribution, the
user can proceed as described above.
Setting model parameters and hypothesis testing
In an associated article6, we detailed the parameter estimation
procedure to derive default parameters that capture clinically
observed temporal changes and variability in test sensitivities,
incubation and infectious periods, as well as times to symptom
onset. However, a user may want to assess the efficacy of an
NPI strategy that uses a novel diagnostic test, or is directed
against a novel virus variant that exhibits different viral kinetics.
For this reason, COVIDStrategyCalculator allows users to adapt
all parameters related to viral dynamics, diagnostics, as well as
the proportion of asymptomatic cases. When switching to the
‘‘parameters’’ tab Figure 3A, field 2, the user is taken to the win-
dow depicted in Figure 3B.
The first four rows (shaded area in Figure 3B) allow to alter the
time course of infection, i.e. (i) the average incubation time
(= time before symptom onset), (ii) the fraction of this incubation
time, where the infected individual is not infectious and the virus
is not detectable yet, (iii) the average duration of the symptomatic
phase, where the individual is infectious and the virus detectable,
(iv) as well as the average duration of the post-infectious phase,
where the virus is detectable, but no longer infectious. Changing
these parameters will alter the efficacy of NPI strategies (e.g.,
how long the duration of a quarantine needs to be), the time-
dependent sensitivity of the diagnostic assay (i.e., when tests
would bemost beneficial), as well as the efficacy of symptomatic
screening during quarantine.
The next three lines (fields 17–19 in Figure 3B) allow the user to
alter the characteristics of the diagnostic tests performed, i.e. (v)
maximum sensitivity of the PCR test (field 17), as well as (vi) its
specificity (field 18). The (vii) sensitivity of antigen-based RDT is
usually measured relative to PCR results13–16 and can be set in
field 19 of Figure 3B. The temporal changes in test sensitivity
forRDTare assumed tobecomparablewith thoseofPCR testing,
but can be altered as described below. The RDT specificity is
assumed to be equal to the PCR specificity, because, at least
in low-prevalence/low pretest probability settings, a positive
RDT result is typically confirmed by a PCR test.17–20 Generally,
upon a SARS-CoV-2 diagnosis it is assumed in the COVIDStrate-
gyCalculator that the individuals go into isolation and no longer
pose a risk. Thus, altering diagnostic parameters (v–vii; fields
17–19) allows to change the efficacy of the tests to identify in-
fected individuals, while the inputs (v–vii) shift the magnitude of
the false omission rate. The temporal profile of the false omission
rate can be altered by changing viral dynamics parameters (i–iv;
fields in the shaded area in Figure 3B). The resultant temporal
test sensitivity can be inspected in Figure 2A, field 1).
Finally, (viii) the proportion of asymptomatic cases can be
changed in field 20 of Figure 3B. This parameter alters the effec-
tiveness of ‘‘symptom screening’’ in NPI strategies.
Altering any of the parameters allows the user to perform hy-
pothesis testing: for example, ‘‘How much worse would an NPIperform if the test sensitivity was lower?’’ ‘‘. if the virus incuba-
tion time was shorter but the infectious phase longer?’’ or ‘‘ . if
the proportion of asymptomatic cases was larger,’’ etc.
Prevalence estimation and assessing NPI strategies in
populations with mixed ‘‘infection age’’
In COVIDStrategyCalculator, the user has the possibility to
perform a prevalence estimation given a user-provided incidence
history of the past 5 weeks. The user can also use this utility to
generate apopulationwithmixed ‘‘infection age’’whencomputing
NPI strategies in the ‘‘quarantine for incoming travelers’’ mode.
To perform a prevalence estimation, the user inputs the inci-
dence history of the past 5 weeks in the region of interest (Fig-
ure 3C, field 22). The incidence reports are typically reported
as the number of cases per week and 100,000 inhabitants by na-
tional or supra-national health authorities, such as the European
Centre for Disease Control and Prevention. In addition to the inci-
dence reports, an estimate of the presumed proportion of cases
that are actually reported (Figure 3C, field 23) can be provided.
This number may vary widely between different regions and de-
pends on national testing strategies. Upon pressing ‘‘estimate
prevalence,’’ COVIDStrategyCalculator will estimate the preva-
lence based on the intra-host SARS-CoV-2 dynamics model
(Figure 1A), as detailed in an associated article. The routine will
calculate the probability distribution over the states of themodel,
as well as the ‘‘total prevalence’’ and the prevalence of individ-
uals who are currently infectious or pre-infectious. Uncertainty
ranges are calculated based on the extreme parameter values
provided by the user (Figure 3B, fields 13–14).
The estimated probability distribution can beused for assessing
NPI strategies by checking ‘‘use,’’ which will take the user back to
the NPI configuration window (Figure 3A). While this feature of the
softwareallows toestimate theprevalence ina settingof interest, it
canalsobeused toset the initial distributions for theassessmentof
NPI strategies, e.g., by altering ‘‘incidence’’ values to deduce a
suitable initial distribution over the model states.
Identifying efficient combined NPI + testing strategies
Another application of the COVIDStrategyCalculator is to identify
NPI strategies that use testing to shorten quarantine or isolation
periods. Essentially, this requires finding testing and quarantine
strategies that are equivalent or non-inferior to established stra-
tegies. To identify those strategies, the user starts by assessing
the efficacy (relative risk, risk reduction) of an established gold
standard NPI as outlined in the section configuring and simu-
lating an NPI strategy (e.g., 14 days quarantine as suggested
by the WHO1). Subsequently, the user could configure a com-
bined strategy, where testing shortens the quarantine or isolation
period; for example, by placing a test at the end of the quarantine
period. By repeating the procedure with different quarantine du-
rations the user could find the shortest combined test + quaran-
tine strategy that has a non-inferior efficacy (relative risk, risk
reduction) to the gold standard NPI.
DISCUSSION
While vaccination programs are being rolled out in most coun-
tries in early 2021, it is not yet clear when the critical level of
vaccination will be achieved globally, or whether the SARPatterns 2, 100264, June 11, 2021 5
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OPEN ACCESS DescriptorS-CoV-2 virus will become endemic.21–23 In both cases, non-
pharmaceutical control strategies, including testing, isolation,
and quarantine, will remain an integral part of controlling the
further spread of SARS-CoV-2. We have developed an open-
source software that allows decision makers to evaluate and
deduce non-pharmaceutical SARS-CoV-2 mitigation strategies
based on quarantine, testing, and isolation. The software was
designed to provide maximum flexibility to the user combined
with intuitive operability. The web version of the software runs
in a platform-independent manner in the bowser (https://
COVIDStrategyCalculator.github.io), while offline versions for
all major operating systems are available for download from
https://github.com/COVIDStrategyCalculator/COVIDStrategy
Calculator. The underlying mathematical models and methods,
which reproduce the spectrum of clinically observed infection
dynamics from in-house and published studies, are presented
in an associated paper.6 As many public health experts may
not be comfortable with implementing the underlying methods
themselves, the main purpose of the software is to provide a
tool that allows configuring custom NPI strategies and perform
hypothesis testing for rational, evidence-based design of non-
pharmaceutical control strategies.
An imminentquestion thatmay arise in the near future iswhether
NPI strategies need to be adapted in the context of increasing
amounts of infectionswith novel, potentially more contagious var-
iants.24–26 For example, as of March 2021, the variant of concern
B.1.1.7 (also 202012/01 or 20B/501Y.V1 depending on nomencla-
ture) is on the rise in theUSandmost European countries, and has
become the major circulating variant in the UK. Early reports27
describe potentially distinct viral kinetics, based on seven densely
sampled individuals infected with B.1.1.7. While more data are
required to ascertain potentially different viral kinetics in the light
of the observed inter-individual variability, our software is already
able to accommodate different viral kinetics, e.g., for hypothesis
testing. For example,Kissler et al.27 suggest that theviral load rises
and drops slower in B.1.1.7 compared with non-B.1.1.7, but
achieves higher viral titers for prolonged durations pre- and post-
peak viral loads. In our software, these viral kinetic alterations
can be implemented by increasing the ‘‘mean duration of incuba-
tion,’’ decreasing the ‘‘percentage thereof pre-detectable’’ and
increasing the ‘‘mean duration of the symptomatic period’’ in the
‘‘parameters tab’’ (compare the section setting model parameters
and hypothesis testing). Whenwe performed calculationswith the
aforementioned parameter changes in COVIDStrategyCalculator,
we generally observed that longer durations of quarantine would
be needed to achieve risk reductions that are non-inferior to
non-B.1.1.7. However, when combining quarantine with testing,
the differences were less pronounced. In the future, it is planned
to update the default parameter settings as soon as sufficient
intro-host viral kinetic data for the novel variants is available.
Currently, many novel diagnostic options are becoming avail-
able. Among these are antigen-based diagnostics for self-
testing. The diagnostic performance of these tests is usually
compared with PCR testing of nasopharyngeal swabs.13–16 In
COVIDStrategyCalculator, it is straightforward to incorporate
the relative sensitivity of these tests for hypothesis testing and
for the design of NPI strategies that utilize self-testing, as out-
lined in the section setting model parameters and hypothesis
testing.6 Patterns 2, 100264, June 11, 2021Output parameters in the COVIDStrategyCalculator, such as
the ‘‘relative risk’’ or the ‘‘risk reduction’’ are calculated with re-
gard to the baseline risk of ‘‘no NPIs and unrestricted entry’’
(Equation 2). Different baselines can also be computed based
on the software outputs: one can compute the relative risk for in-
terventions A and B, respectively, with regard to the default
baseline ‘‘B’’ in COVIDStrategyCalculator. Let us call them
RRðA =BÞ and RRðB =BÞ. The fraction RRðA=BÞRRðB=BÞ = RRðA =BÞ) will
give the relative risk of intervention A with regard to intervention
B. Similarly, one may compute the relative risk of a fixed strategy
in a variant of concern versus a non-B.1.1.7 variant.
The COVIDStrategyCalculator allows to assess the efficacy of
arbitrary NPI strategies with regard to the reduction in onward
transmission emanating from a (potentially) infected individual.
Epidemiological modeling (e.g., SEIR) often addresses the ques-
tion of disease spread in a population, as a consequence of
different (hypothetical) interventions,28 such as, for example,
‘‘how many individuals are expected to be infected, if a 96%
effective vaccine was applied to 60% of individuals,’’ or ‘‘ . if
an NPIs strategy reduced transmission by 70% and was con-
ducted by 50% of the individuals.’’ The efficacy parameters for
these (hypothetical) interventions are often assumed. However,
COVIDStrategyCalculator provides the required parameters of
efficacy (‘‘relative risk,’’ ‘‘risk reduction’’) that can be multiplied
with default (‘‘no intervention’’) parameters used in epidemiolog-
ical models. The NPI efficacy estimates may also be used in
conjunction with parameters of vaccine efficacy29–31 to evaluate
the concomitant effects of both public health interventions.
In summary, we present COVIDStrategyCalculator, which is a
free, platform-independent, software that computes the efficacy
of NPI strategies with regard to reducing SARS-CoV-2 transmis-
sion. The tool is based on a stochastic model that resembles the
within-host viral dynamics and temporal test sensitivities. The
software allows users to configure and evaluate arbitrary NPI
strategies and can be used for hypothesis testing, e.g., with re-
gard to designing NPIs to contain novel variants, or utilizing novel
diagnostic tests into NPI strategies.
The web version of the software can be used through https://






Further information and requests for resources should be directed to and will
be fulfilled by the lead contact, Max von Kleist (kleistm@rki.de).
Materials availability
This study did not generate new materials.
Data and code availability




The software is as a standalone graphical user interface that can either be run
from a browser (https://COVIDStrategyCalculator.github.io) or offline for Win-
dows, Mac, and Linux. Source codes and pre-built executables are freely
available from https://github.com/COVIDStrategyCalculator/COVIDStrategy
Calculator. The tool itself is implemented in C++ using the Qt (version 5.9.5)
ll
OPEN ACCESSDescriptorand Eigen (version 3.3.7) library and is provided under the GNU LGPLv3 li-
cense. The web version uses Qt for WebAssembly.
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